{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:04:27Z","timestamp":1789203867490,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ygyno.2014.08.013","type":"journal-article","created":{"date-parts":[[2014,8,16]],"date-time":"2014-08-16T02:45:24Z","timestamp":1408157124000},"page":"359-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Role of Toll-like receptors in cervical, endometrial and ovarian cancers: A review"],"prefix":"10.1016","volume":"135","author":[{"given":"Nader","family":"Husseinzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-9794","authenticated-orcid":false,"given":"Sara Madison","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.08.013_bb0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","article-title":"Toll-like receptors in innate immunity","volume":"17","author":"Takeda","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0030","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0035","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1007\/s00018-008-8064-8","article-title":"TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme","volume":"65","author":"Verstepen","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0040","first-page":"437","article-title":"Signaling pathways of the TNF superfamily: a double edged sword","volume":"134","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12272-012-0802-7","article-title":"Roles of toll-like receptors in cancer: a double-edged sword for defense and offense","volume":"35","author":"Basith","year":"2012","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrc2541","article-title":"Toll-like receptors and cancer. Perspectives","volume":"9","author":"Rakoff-Nahoum","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2014.08.013_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0060","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1078-0432.CCR-12-0408","article-title":"Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity","volume":"19","author":"Ridnour","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2014.08.013_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12307-009-0022-y","article-title":"Cancer cells expressing toll-like receptors and the tumor microenvironment","volume":"2","author":"Sato","year":"2009","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.2.6.566","article-title":"Death receptor activation complexes: it takes two to activate TNF receptor 1","volume":"2","author":"Sheikh","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clon.2006.11.013","article-title":"The transcription factor NF-\u03baB and cancer","volume":"19","author":"Escarcega","year":"2007","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0080","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/humrep\/deh775","article-title":"Characterization of toll-like receptors in the female reproductive tract","volume":"20","author":"Fazeli","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ijc.28364","article-title":"Genetic variation in the TLR and NF-\u03baB pathways and cervical and vulvar cancer risk: a population based case control study","volume":"134","author":"Bodelon","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1753425910392934","article-title":"Expression of integrins and toll-like receptors in cervical cancer: effect of infectious agents","volume":"18","author":"Werner","year":"2012","journal-title":"Innate Immun"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0095","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1248\/bpb.28.886","article-title":"Tissue specific mRNA expression profiles of human toll like receptors and related genes","volume":"28","author":"Nishimura","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/mc.20325","article-title":"Increased toll-like receptor 9 expression in cervical neoplasia","volume":"46","author":"Lee","year":"2007","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00262-010-0825-1","article-title":"Expression of toll-like receptor 4 is downregulated during progression of cervical neoplasia","volume":"59","author":"Yu","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0110","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","article-title":"TLR-9 expression and function is abolished by the cervical cancer associated HPV type 16","volume":"178","author":"Hasan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-1438.2007.01008.x","article-title":"Increased expression of toll like receptor 5 during progression of cervical neoplasia","volume":"18","author":"Kim","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1477-7827-6-40","article-title":"TLR3 and TRL4 expression in healthy and diseased human endometrium","volume":"6","author":"Allorn","year":"2008","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0125","article-title":"Toll-like receptor and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk","volume":"10: 382","author":"Ashton","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0130","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-12-1019","article-title":"Ran S.TLR 4 is a novel determinant of response to paclitaxel in breast cancer","volume":"12","author":"Rajput","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00262-008-0650-y","article-title":"Toll like receptor expression in normal ovary and ovarian tumors","volume":"58","author":"Zhou","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bbrc.2011.05.063","article-title":"TLR4 activates NF-\u03baB in human ovarian granulosa tumor cells","volume":"409","author":"Woods","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0155","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1113401","article-title":"Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function","volume":"309","author":"Peng","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0160","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1349-7006.2010.01491.x","article-title":"Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors","volume":"101","author":"Berger","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-11-1625","article-title":"VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC","volume":"18","author":"Lu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0170","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N","article-title":"The role of MyD88 and TLR4 in the LPS \u2014 mimetic activity of Taxol","volume":"31","author":"Byrd-Leifer","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0175","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/0008-5472.CAN-05-3948","article-title":"TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer","volume":"66","author":"Kelly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0180","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/ijc.23737","article-title":"Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel","volume":"123","author":"Tichomirowa","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0185","first-page":"13","article-title":"Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma","volume":"5","author":"Brueseke","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0190","author":"Monk"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0195","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00262-010-0914-1","article-title":"Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers","volume":"59","author":"Geller","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0200","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1415","article-title":"Inflammation and necrosis promote tumor growth","volume":"4","author":"Vakkila","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0205","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/PPO.0b013e3181eaca65","article-title":"Toll-like receptor agonists: are they good adjuvants?","volume":"16","author":"Gnjatic","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0210","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0215","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0220","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","article-title":"TLR3 can directly trigger apoptosis in human cancer cells","volume":"176","author":"Salaun","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ygyno.2014.08.013_bb0225","first-page":"949","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.ygyno.2014.08.013_bb0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/11316930-000000000-00000","article-title":"CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer","volume":"23","author":"Murad","year":"2009","journal-title":"BioDrugs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814012669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814012669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T09:57:42Z","timestamp":1538301462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814012669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0090825814012669"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.08.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Toll-like receptors in cervical, endometrial and ovarian cancers: A review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}